13 October 2021

Moderna

You will undoubtedly have heard Moderna’s name in recent months as a developer of one of the vaccines for COVID-19.

by Michael Bray

Research Analyst

Group 10Created with Sketch.
Price
$449.38
Group 11Created with Sketch.
52 Week High-Low
$497.49—$60.12
Page 1Created with Sketch.
Net Yield
0%
Group 12Created with Sketch.
Hist / Pros Per
NA/15.1
Page 1Created with Sketch.
Equity Market Cap
$181,390

Moderna has developed proprietary technologies to create mRNA (messenger ribonucleic acid) sequences that cells recognise and respond to as if they are produced in our body.  Most importantly, this technology can prompt cells in the body to make proteins. Nearly every function in the human body (normal and disease-related) is carried out by one or more proteins.  mRNA technology instructs the body to make particular proteins that can help treat or prevent disease. Once these instructions are in the cell, human biology takes over: ribosomes (the body’s factory for making proteins) contained in the cells read the code and build the protein.

We know mRNA works in providing high protection against COVID-19, but it also has the potential to treat many other diseases such as cancer, HIV, cardiovascular, respiratory, autoimmune and rare genetic diseases. mRNA can both temporarily boost the production of needed proteins or inhibit the production of harmful ones – this is likened to using the body’s own cellular machinery as an on-demand drug factory. However until further substantive clinical data is collected, the potential of mRNA remains confined to theory.

Managing your wealth

Managing your wealth

Understanding Finance

Helping clients understand what we do is key to building relationships. To explain some of the industry jargon that creeps into our world, we’ve pulled together a section of our site to help.


Also in this issue

As part of our focus on providing a high quality, personalised investment service, we look to support our investment managers in their decision making when it comes to constructing client portfolios.

We were delighted to win the award for best App / Portal of the year at the 2021 Brand Management & Reputation Awards, from Citywealth.

The Affordable Art Fair is back and we are delighted to be sponsoring it again.

Autumn Issue Thirty Six